(c)
reporting of suspected unexpected serious adverse reactions by the sponsor to the Eudravigilance database; and
← anx_I__cpt_4__point_20__point_b__text_1 · All articles · anx_I__cpt_4__point_20__point_c__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.